Balasubramanian V
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Balasubramanian V has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
Nagakumar Bharatham
Bugworks Research India Pvt. Ltd., Center for Cellular & Molecular Platforms, National Center for Biological Sciences, Bangalore, India
4 shared publicationsRanga Rao
Bugworks Research India Pvt. Ltd., Center for Cellular & Molecular Platforms, National Center for Biological Sciences, Bangalore, India
4 shared publications- Santanu Datta
Bugworks Research India Pvt. Ltd. Center for Cellular & Molecular Platforms, National Center for Biological Sciences, GKVK Campus, Bellary Road, Bangalore, India
4 shared publications Shahul Hameed P
Bugworks Research India Pvt. Ltd., Center for Cellular & Molecular Platforms, National Center for Biological Sciences, Bangalore, India
4 shared publications- Sreevalli Sharma
Bugworks Research India Pvt. Ltd. Center for Cellular & Molecular Platforms, National Center for Biological Sciences, GKVK Campus, Bellary Road, Bangalore, India
4 shared publications Suryanarayanan Venkatesan
Bugworks Research India Pvt. Ltd., Center for Cellular & Molecular Platforms, National Center for Biological Sciences, Bangalore, India
4 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1666
Structural interactions of BWC0977 with Klebsiella pneumoniae topoisomerase IV and biochemical basis of its broad-spectrum activity
Antimicrobial resistance is a growing global health crisis driving the urgent need for effective broad-spectrum antibiotics. BWC0977 is a pyrazino-oxazinone based novel bacterial topoisomerase inhibitor (NBTI) currently in Phase 1 clinical trials and demonstrates potent activity against multidrug-resistant Gram-negative and Gram-positive bacteria. It targets both DNA gyrase and topoisomerase IV with balanced low-nanomolar potencies, showing remarkable superiority over ciprofloxacin and gepotidacin. We report the first 3.05 Å cocrystal structure of BWC0977 bound to Klebsiella pneumoniae topoisomerase IV, revealing its binding mode and interaction residues. The reduced inhibition of BWC0977 against purified gyrase enzymes carrying an individual mutation at these residues supports the relevance of these molecular interactions. Mutational analyses in Escherichia coli strains show that single target mutations in gyrA or parC do not confer resistance, while simultaneous mutations in both genes result in over 250-fold reduced susceptibility. The compound also demonstrates more than 5000-fold selectivity for bacterial over human topoisomerases and retains efficacy against fluoroquinolone and carbapenem-resistant clinical isolates. Together, these structural, biochemical, and microbiological insights elucidate BWC0977’s broad-spectrum antibacterial activity and reduced vulnerability to resistance, establishing it as a promising next-generation antibiotic to address the global threat of antimicrobial resistance.
- 25 November 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1666
Open AccessStructural interactions of BWC0977 with Klebsiella pneumoniae topoisomerase IV and biochemical basis of its broad-spectrum activity
Antimicrobial resistance is a growing global health crisis driving the urgent need for effective broad-spectrum antibiotics. BWC0977 is a pyrazino-oxazinone based novel bacterial topoisomerase inhibitor (NBTI) currently in Phase 1 clinical trials and demonstrates potent activity against multidrug-resistant Gram-negative and Gram-positive bacteria. It targets both DNA gyrase and topoisomerase IV with balanced low-nanomolar potencies, showing remarkable superiority over ciprofloxacin and gepotidacin. We report the first 3.05 Å cocrystal structure of BWC0977 bound to Klebsiella pneumoniae topoisomerase IV, revealing its binding mode and interaction residues. The reduced inhibition of BWC0977 against purified gyrase enzymes carrying an individual mutation at these residues supports the relevance of these molecular interactions. Mutational analyses in Escherichia coli strains show that single target mutations in gyrA or parC do not confer resistance, while simultaneous mutations in both genes result in over 250-fold reduced susceptibility. The compound also demonstrates more than 5000-fold selectivity for bacterial over human topoisomerases and retains efficacy against fluoroquinolone and carbapenem-resistant clinical isolates. Together, these structural, biochemical, and microbiological insights elucidate BWC0977’s broad-spectrum antibacterial activity and reduced vulnerability to resistance, establishing it as a promising next-generation antibiotic to address the global threat of antimicrobial resistance.
- Open Access
- 28 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-2
Author Correction: BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections
- 28 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-2
Open AccessAuthor Correction: BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections
- Open Access
- 13 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-2
Author Correction: BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections
- 13 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-2
Open AccessAuthor Correction: BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections
- Open Access
- 18 September 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-20
BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections
The global crisis of antimicrobial resistance (AMR) necessitates the development of broad-spectrum antibacterial drugs effective against multi-drug resistant (MDR) pathogens. BWC0977, a Novel Bacterial Topoisomerase Inhibitor (NBTI) selectively inhibits bacterial DNA replication via inhibition of DNA gyrase and topoisomerase IV. BWC0977 exhibited a minimum inhibitory concentration (MIC90) of 0.03–2 µg/mL against a global panel of MDR Gram-negative bacteria including Enterobacterales and non-fermenters, Gram-positive bacteria, anaerobes and biothreat pathogens. BWC0977 retains activity against isolates resistant to fluoroquinolones (FQs), carbapenems and colistin and demonstrates efficacy against multiple pathogens in two rodent species with significantly higher drug levels in the epithelial lining fluid of infected lungs. In healthy volunteers, single-ascending doses of BWC0977 administered intravenously (https://clinicaltrials.gov/study/NCT05088421) was found to be safe, well tolerated (primary endpoint) and achieved dose-proportional exposures (secondary endpoint) consistent with modelled data from preclinical studies. Here, we show that BWC0977 has the potential to treat a range of critical-care infections including MDR bacterial pneumonias.
- 18 September 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-20
Open AccessBWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections
The global crisis of antimicrobial resistance (AMR) necessitates the development of broad-spectrum antibacterial drugs effective against multi-drug resistant (MDR) pathogens. BWC0977, a Novel Bacterial Topoisomerase Inhibitor (NBTI) selectively inhibits bacterial DNA replication via inhibition of DNA gyrase and topoisomerase IV. BWC0977 exhibited a minimum inhibitory concentration (MIC90) of 0.03–2 µg/mL against a global panel of MDR Gram-negative bacteria including Enterobacterales and non-fermenters, Gram-positive bacteria, anaerobes and biothreat pathogens. BWC0977 retains activity against isolates resistant to fluoroquinolones (FQs), carbapenems and colistin and demonstrates efficacy against multiple pathogens in two rodent species with significantly higher drug levels in the epithelial lining fluid of infected lungs. In healthy volunteers, single-ascending doses of BWC0977 administered intravenously (https://clinicaltrials.gov/study/NCT05088421) was found to be safe, well tolerated (primary endpoint) and achieved dose-proportional exposures (secondary endpoint) consistent with modelled data from preclinical studies. Here, we show that BWC0977 has the potential to treat a range of critical-care infections including MDR bacterial pneumonias.